Trial Profile
A Phase 2 Multicenter, Randomized, Open Label, Parallel Assignment, Pilot Study to Assess the Efficacy and Safety of Reparixin Following Islet Transplantation in Patients With Type 1 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Reparixin (Primary)
- Indications Delayed graft function
- Focus Therapeutic Use
- Sponsors Dompe Farmaceutici
- 27 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Jun 2014 New trial record
- 30 Aug 2012